Megan Four
A5029945341- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Biosimilars and Bioanalytical Methods
- Insect Resistance and Genetics
- Viral Infectious Diseases and Gene Expression in Insects
- Immunotherapy and Immune Responses
University of Pennsylvania
2022-2024
Abstract We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR (huCART19) in multiple myeloma (MM) patients responding to third- later-line therapy (phase A, N = 10) high-risk first-line B, 20), followed by early lenalidomide pomalidomide maintenance. observed no high-grade cytokine release syndrome (CRS) and only one instance low-grade neurologic toxicity. Among 15 subjects measurable disease, 10 exhibited partial...
7004 Background: A substantial proportion of patients (pts) with relapsed/refractory (R/R) non-Hodgkin lymphomas (NHL) will not derive a long-term benefit from the existing anti-CD19 chimeric antigen receptor (CAR) T cells. To enhance therapeutic efficacy, we have engineered huCART19-IL18, 4 th generation 4-1BB construct, armored ability to secrete pro-inflammatory cytokine, IL-18. Methods: This is first-in-human trial using huCART19-IL18 for CD19+ B-cell malignancies (NCT04684563)....
Introduction: Lymphoma (NHL) patients (pts) relapsing/refractory (R/R) to anti-CD19 chimeric antigen receptor T-cells (CART) represent a challenging group in need of effective therapies. HuCART19-IL18 is 4th generation 4-1BB CART product designed express humanized CAR and secrete interleukin 18, pro-inflammatory cytokine shown enhance efficacy pre-clinical models. Its scFv may allow for better persistence, the additional use novel expedited 3-day manufacturing protocol improve product's...
<div>Abstract<p>We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR (huCART19) in multiple myeloma (MM) patients responding to third- later-line therapy (phase A, <i>N</i> = 10) high-risk first-line B, 20), followed by early lenalidomide pomalidomide maintenance. We observed no high-grade cytokine release syndrome (CRS) and only one instance low-grade neurologic toxicity. Among 15 subjects...
<div>Abstract<p>We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR (huCART19) in multiple myeloma (MM) patients responding to third- later-line therapy (phase A, <i>N</i> = 10) high-risk first-line B, 20), followed by early lenalidomide pomalidomide maintenance. We observed no high-grade cytokine release syndrome (CRS) and only one instance low-grade neurologic toxicity. Among 15 subjects...